Trastuzumab was tested clinically in several phase I–III trials in patients with a variety of solid tumors and is currently approved as monotherapy or in combination with chemotherapy for patients with HER2-positive early BC (EBC), MBC, and advanced gastric cancer (AGC). Here, ERBB2 is linked to breast cancer.